{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:27:16Z","timestamp":1761895636921},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1097\/jcp.0b013e318287019c","type":"journal-article","created":{"date-parts":[[2013,2,15]],"date-time":"2013-02-15T08:47:44Z","timestamp":1360918064000},"page":"231-235","source":"Crossref","is-referenced-by-count":23,"title":["Effectiveness of Short-Term Olanzapine in Patients With Bipolar I Disorder, With or Without Comorbidity With Substance Use Disorder"],"prefix":"10.1097","volume":"33","author":[{"given":"Gabriele","family":"Sani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios D.","family":"Kotzalidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"V\u00f6hringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Pucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Savoja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano Maria","family":"Tamorri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Mazzarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Pacchiarotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla Ludovica","family":"Telesforo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Ferracuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Brugnoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Ambrosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Caloro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Del Casale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia E.","family":"Koukopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derick E.","family":"Vergne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Nassir","family":"Ghaemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-15-20210128","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","article-title":". Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.","volume":"264","author":"Regier","year":"1990","journal-title":"JAMA"},{"key":"R2-15-20210128","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1001\/archpsyc.1994.03950010008002","article-title":". Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.","volume":"51","author":"Kessler","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"R3-15-20210128","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","article-title":". Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R4-15-20210128","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/archpsyc.61.8.807","article-title":". Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.","volume":"61","author":"Grant","year":"2004","journal-title":"Arch Gen Psychiatry"},{"issue":"suppl 3","key":"R5-15-20210128","first-page":"19","article-title":"The relationship between substance abuse and bipolar disorder.","volume":"56","author":"Brady","year":"1995","journal-title":"J Clin Psychiatry"},{"key":"R6-15-20210128","first-page":"118","article-title":". Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study.","volume":"56","author":"Brady","year":"1995","journal-title":"J Clin Psychiatry"},{"key":"R7-15-20210128","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1176\/ajp.156.7.1122","article-title":"Valproate for alcoholics with bipolar disorder.","volume":"156","author":"Sonne","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R8-15-20210128","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archpsyc.62.1.37","article-title":". Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.","volume":"62","author":"Salloum","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R9-15-20210128","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1037\/1064-1297.10.3.276","article-title":". Carbamazepine in the treatment of cocaine dependence: subtyping by affective disorder.","volume":"10","author":"Brady","year":"2002","journal-title":"Exp Clin Psychopharmacol"},{"key":"R10-15-20210128","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4088\/JCP.v64n0213","article-title":". Lamotrigine in patients with bipolar disorder and cocaine dependence.","volume":"64","author":"Brown","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R11-15-20210128","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jad.2006.02.001","article-title":". Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study.","volume":"93","author":"Brown","year":"2006","journal-title":"J Affect Disord"},{"key":"R12-15-20210128","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1399-5618.2006.00292.x","article-title":"Effects of lamotrigine in patients with bipolar disorder and alcohol dependence.","volume":"8","author":"Rubio","year":"2006","journal-title":"Bipolar Disord"},{"key":"R13-15-20210128","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1176\/ajp.147.5.655","article-title":". Lithium treatment for cocaine abusers with bipolar spectrum disorder.","volume":"147","author":"Nunes","year":"1990","journal-title":"Am J Psychiatry"},{"key":"R14-15-20210128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00004583-199802000-00009","article-title":". Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency.","volume":"37","author":"Geller","year":"1998","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R15-15-20210128","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1034\/j.1399-5618.2002.02229.x","article-title":". Quetiapine in bipolar disorder and cocaine dependence.","volume":"4","author":"Brown","year":"2002","journal-title":"Bipolar Disord"},{"key":"R16-15-20210128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/01.jcp.0000106230.36344.b1","article-title":". Quetiapine for alcohol use and craving in bipolar disorder.","volume":"24","author":"Longoria","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R17-15-20210128","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4088\/JCP.v66n0613","article-title":". Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole.","volume":"66","author":"Brown","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R18-15-20210128","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/jcp.0b013e3181602fd4","article-title":". A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence.","volume":"28","author":"Anton","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R19-15-20210128","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/187152710790966731","article-title":"Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence.","volume":"9","author":"Vergne","year":"2010","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"R20-15-20210128","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0740-5472(01)00205-7","article-title":". Olanzapine treatment for patients with schizophrenia and substance abuse.","volume":"21","author":"Littrell","year":"2001","journal-title":"J Subst Abuse Treatment"},{"key":"R21-15-20210128","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.4088\/JCP.v63n1214c","article-title":". Olanzapine treatment for patients with schizophrenia and cocaine abuse.","volume":"63","author":"Tsuang","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R22-15-20210128","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/10550490701389658","article-title":"Comparison of olanzapine to risperidone in substance abusing individuals with schizophrenia.","volume":"16","author":"Akerele","year":"2007","journal-title":"Am J Addict"},{"key":"R23-15-20210128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/01.jcp.0000194624.07611.5e","article-title":". The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report.","volume":"26","author":"Smelson","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R24-15-20210128","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/wnf.0b013e31803354f6","article-title":". Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders.","volume":"30","author":"Gerra","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"R25-15-20210128","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/01.nmd.0000165089.14736.bf","article-title":". Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol.","volume":"193","author":"Sayers","year":"2005","journal-title":"J Nerv Ment Dis"},{"key":"R26-15-20210128","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/01.jcp.0000085417.08426.54","article-title":". Potential use of olanzapine in treatment of substance dependence disorders.","volume":"23","author":"Sattar","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"R27-15-20210128","doi-asserted-by":"crossref","first-page":"969","DOI":"10.4088\/JCP.v64n0819a","article-title":"Olanzapine for cocaine cravings and relapse prevention.","volume":"64","author":"Sattar","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R28-15-20210128","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":". A rating scale for mania: reliability, validity and sensitivity.","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"R29-15-20210128","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.2044-8260.1967.tb00530.x","article-title":"Development of a rating scale for primary depressive illness.","volume":"6","author":"Hamilton","year":"1967","journal-title":"Br J Soc Clin Psychol"},{"key":"R30-15-20210128","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000395069","article-title":"Psychological measurements in psychopharmacology.","volume":"7","author":"Overall","year":"1974","journal-title":"Mod Probl Pharmacopsychiat"},{"key":"R31-15-20210128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2125.1978.tb01676.x","article-title":"Sensitivity and accuracy with the visual analogue scale: a psycho-physical classroom experiment.","volume":"6","author":"Maxwell","year":"1978","journal-title":"Br J Clin Pharmacol"},{"key":"R33-15-20210128","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0920-9964(98)00062-0","article-title":"Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.","volume":"33","author":"Conley","year":"1998","journal-title":"Schizophr Res"},{"key":"R34-15-20210128","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/070674370805300610","article-title":". Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.","volume":"53","author":"van Nimwegen","year":"2008","journal-title":"Can J Psychiatry"},{"key":"R35-15-20210128","first-page":"407","article-title":". Olanzapine attenuates cue-elicited craving for tobacco.","volume":"175","author":"Hutchison","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"R36-15-20210128","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/sj.npp.1300917","article-title":". The effect of olanzapine on craving and alcohol consumption.","volume":"31","author":"Hutchison","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R37-15-20210128","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/10550490802544318","article-title":". Olanzapine in cocaine dependence: a double-blind, placebo-controlled trial.","volume":"18","author":"Hamilton","year":"2009","journal-title":"Am J Addict"},{"key":"R38-15-20210128","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0376-8716(03)00009-7","article-title":". A pilot trial of olanzapine for the treatment of cocaine dependence.","volume":"70","author":"Kampman","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"R39-15-20210128","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s002130050877","article-title":"Differential effects of olanzapine at dopamine D1 and D2 receptors in dopamine depleted animals.","volume":"142","author":"Ninan","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"R40-15-20210128","first-page":"774","article-title":"Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens.","volume":"288","author":"Kuroki","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"R41-15-20210128","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s002130050551","article-title":". Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum.","volume":"136","author":"Li","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"R42-15-20210128","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s002130050834","article-title":"The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors.","volume":"141","author":"Zhang","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"R43-15-20210128","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1038\/sj.npp.1300264","article-title":". Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction.","volume":"28","author":"Hutchison","year":"2003","journal-title":"Neuropsychopharmacology"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e318287019c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T15:15:12Z","timestamp":1688051712000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201304000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318287019c","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}